Consolidated Results First Quarter Ended June 30, 2014

- 1. Overview
- 2. Financial Position
- 3. Segment Information

July 31, 2014 Ajinomoto Co., Inc.

МЛИОМОТО. 1. (1) Overview of Results

(¥ Billion)

	AprJune 2014	AprJune 2013	YoY CI	hange	FY2014 (Forecast)	Progress
	(A)	20.0	Amount	%	(B)	A/B
Net sales	227.6	233.7	-6.1	-3%	1,008.0	23%
Domestic Food Products	71.0	70.1	0.8	1%	312.3	23%
Overseas Food Products	74.4	71.4	3.0	4%	322.2	23%
Bioscience Products & Fine Chemicals	53.2	55.0	-1.9	-3%	238.4	22%
Pharmaceuticals	9.4	16.8	-7.3	-44%	44.0	21%
Other Business	19.7	20.4	-0.7	-3%	91.1	22%
Operating income	13.3	15.3	-1.9	-13%	70.0	19%
Domestic Food Products	5.0	6.1	-1.2	-19%	28.8	17%
Overseas Food Products	7.8	6.1	1.6	26%	28.2	28%
Bioscience Products & Fine Chemicals	0.8	2.5	-1.7	-69%	9.7	8%
Pharmaceuticals	0.2	0.4	-0.2	-56%	3.5	5%
Other Business	-0.4	0.0	-0.4	—	-0.2	198%
Ordinary income	15.5	17.2	-1.7	-10%	75.0	21%
Net income	10.9	11.9	-1.0	-8%	44.0	25%
Exchange rate JPY/USD	102.17	98.78			100.0	
JPY/EUR	140.07	128.95			130.0	

Notes:

- 1. From FY2014, sales promotion discounts, etc. are deducted from net sales rather than being recorded in selling, general and administrative expenses. In addition, under this accounting treatment the estimated amount is recorded when sales are recorded rather than when the amount to be paid is determined.
- 2. Results for FY2013 have been restated to reflect the above changes (for this and all following slides).





1. (2) Comments on Results for the First Three Months of FY2014

Net sales decreased overall due to impact of spin-off of infusion and dialysis business units in Pharmaceuticals and decrease in sales of feed-use amino acids, despite growth in sales of Overseas Food Products and Domestic Food Products.

Operating income decreased overall due to lower income in every segment except Overseas Food Products, where income grew strongly.

Net sales / Operating income

(¥ Billion)

	AprJune	AprJune	Change		Full-year	Progress
	2014	2013	Amount	%	Forecast	
Net sales	227.6	233.7	-6.1	-3%	1,008.0	23%
Cost of sales	150.5	155.5	-5.0	-3%	-	-
SG&A	63.8	62.9	8.0	1%	-	-
Operating income	13.3	15.3	-1.9	-13%	70.0	19%

1. Impact of Exchange rate for currency translation exchange rate Sales -¥0.8 billion; operating income -¥0.5 billion

(YoY) Exchange rate for trade of main overseas subsidiaries

Sales approx. ¥1.0 billion; operating income approx. ¥1.0 billion

2. Impact of Fermentation raw materials and fuel prices approx. ¥1.0 billion raw material & Domestic food products raw materials approx. -¥0.3 billion

fuel prices (YoY)

3. Cost reductions Domestic food products approx. ¥0.6 billion

(YoY) Pharmaceuticals approx. ¥0.4 billion (-: Cost increase)





JINOMOTO. 1. (3) Comments on Results for the First Three Months of FY2014

Ordinary income

(¥ Billion)

	AprJune	AprJune	Change		Full-year	Progress
	2014	2013	Amount	%	Forecast	
Non-operating income (net)	2.2	1.9	0.2	11%		-
Ordinary income	15.5	17.2	-1.7	-10%	75.0	21%

* None

Net income

	AprJune	AprJune	Cha	nge	Full-year	Progress
	2014	2013	Amount	%	Forecast	
Extraordinary *1 gains	0.7	1.3	-0.6	-48%	-	-
Extraordinary *2 losses	0.5	1.1	-0.6	-57%	-	-
Income taxes etc.	2.5	3.6	-1.1	-30%	-	-
Minority interests	2.2	1.9	0.3	17%	-	-
Net income	10.9	11.9	-1.0	-8%	44.0	25%

- *1 Insurance income ¥0.0 billion (¥1.2 billion decrease)
- *1 Gain on bad debts recovered ¥0.6 billion (¥0.6 billion increase)
- *2 Loss on liquidation of affiliates ¥0.0 billion (¥0.6 billion decrease)




JINOMOTO. 2. Financial Position

Net

assets

655.5

Incl. Minority 60.6 interests



Fixed

assets 545.0

¥6.2 billion decrease in total assets from March 31, 2014

*Decrease in yen values of the balance sheets of overseas subsidiaries after currency translation

Cash Flow

(¥ Billion)

	June 2014	June 2013	Change
1. CF from operating activities	23.0	-0.3	23.3
2. CF from investing activities	-10.0	-28.3	18.3
3. CF from financing activities	-2.8	-11.4	8.6
4. Cash and cash equivalents	140.0	144.5	-4.5
FCF(1+2)	12.9	-28.6	41.6

*Cash out is shown with -.

Capital expenditures	-9.8	-13.5	3.6
Depreciation and amortization	10.5	11.3	-0.8

Interest-bearing Debt


(¥ Billion)

<Reference>

June 2014	June 2013	Change	June 2012
145.9	145.4	0.5	132.9



JINOMOTO. 3. (1) Change by Business Segment



JINOMOTO. 3. (2) Domestic Food Products

		AprJune 2014	Full-year Forecast	Progress	AprJune 2013	Change
Ne	t sales	71.0	312.3	23%	70.1	0.8
	Seasonings & processed foods	44.3	-	-	44.8	-0.5
	Frozen foods	26.7	-	-	25.3	1.4
Op	erating income	5.0	28.8	17%	6.1	-1.2
	Seasonings & processed foods	5.7	-	-	6.5	-0.8
	Frozen foods	1.3	-	-	1.3	-0.0
	Shared companywide expenses	-2.0	-8.5	23%	-1.7	-0.3

^{*1} Decrease in sales due to pullback from last-minute surge in demand for household products at the previous fiscal year end in connection with an increase in the consumption tax, etc.



^{*2} Increase in overall sales due to slight increase in sales in Japan and growth in sales overseas, mainly in North America.

^{*3} Although income from frozen foods remained at the level of the previous first quarter as increased sales covered higher raw material prices, etc., income decreased overall due to lower sales of seasonings & processed foods, increased marketing expenses to stimulate the market, etc.

JINOMOTO₈ 3. (3) Overseas Food Products

(¥ Billion)

		AprJune 2014	Full-year Forecast	Progress	AprJune 2013	Change	
Ne	t sales	74.4	322.2	23%	71.4	3.0	
	Consumer foods	61.9	271.7	23%	58.2	3.8	*1
	Umami seasonings for processed food mfrs.	12.4	50.4	25%	13.2	-0.8	
Op	erating income	7.8	28.2	28%	6.1	1.6	*3
	Shared companywide expenses	-2.6	-11.6	23%	-2.2	-0.4	•

[Effect of currency translation]: Net sales -\(\frac{4}{2}.3\) billion; operating income -\(\frac{4}{2}0.6\) billion

- *1 Increase in sales because of higher sales volume of umami seasoning *AJI-NO-MOTO*, flavor seasonings, etc., despite negative effect of currency translation.
- *2 Decrease in sales because of lower sales volume down of nucleotides, etc., despite positive effect of currency translation.
- *3 Increase in income as increase in sales volume of consumer foods and impact of cost reduction of umami seasonings, etc. offset negative effect of currency translation.

Reference: Consumer foods +¥1.4 billion; umami seasonings for processed food mfrs. ¥0.5 billion



JINOMOTO. 3. (4) Bioscience Products & Fine Chemicals

(¥ Billion)

		AprJune 2014	Full-year Forecast	Progress	AprJune 2013	Change
Ne	t sales	53.2	238.4	22%	55.0	-1.9
	Feed-use amino acids	21.1	102.3	21%	23.7	-2.6
	Amino acids	20.5	-	-	19.0	1.5
	Specialty chemicals	10.7	-	-	11.1	-0.4
Op	erating income	0.8	9.7	8%	2.5	-1.7
	Feed-use amino acids	-1.3	4.0	-32%	0.8	-2.0
	Amino acids	1.4	-	-	1.2	0.2
	Specialty chemicals	2.8	-	-	2.5	0.3
	Shared companywide expenses	-1.8	-7.8	23%	-1.6	-0.2

[Effect of currency translation] : Net sales +¥1.4 billion; operating income +¥0.1 billion

- *1 Decrease in sales due to significant decrease in Lysine unit price, despite positive effect of currency translation.
- *2 Amino acids for pharmaceuticals and foods +¥0.3 billion; pharmaceutical custom manufacturing +¥0.8 billion; sweeteners +¥0.5 billion.
- *3 Sales of chemicals remained at the level of the previous first quarter, but sales of cosmetics decreased due to pullback from last-minute surge in demand at the previous fiscal year end in connection with an increase in the consumption tax, etc.
- *4 Decrease in income because higher income of amino acids for pharmaceuticals and foods and specialty chemicals, etc., did not offset lower income of feed-use amino acids.
 - Reference: Within amino acids, amino acids for pharmaceuticals and foods +¥0.4 billion; pharmaceutical custom manufacturing +¥0.2 billion; sweeteners -¥0.4 billion



JINOMOTO. 3. (5) Pharmaceuticals

(¥ Billion)

		AprJune 2014	Full-year Forecast	Progress	AprJune 2013	Change	
Ne	et sales	9.4	44.0	21%	16.8	-7.3	*1
O	perating income	0.2	3.5	5%	0.4	-0.2	*2
	Shared companywide expenses	-0.4	-1.6	22%	-0.5	0.1	

Sales of products sold through business tie-ups decreased because of growth of competing products, including generics.

Sales based on AJINOMOTO PHARMACEUTICALS CO., LTD. estimated drug prices (% = change from previous fiscal year):

LIVACT	¥3.5 billion	(-6%)	ELENTAL	¥1.9 billion	(-2%)
ATELEC	¥3.2 billion	(-16%)	ACTONEL	¥2.2 billion	(-14%)

FASTIC ¥0.4 billion (-25%)

^{*2} Decrease in income because improved operational efficiency and increased royalty income did not cover the impact of decreases in sales of self-distributed products and products sold through business tie-ups.



^{*1} Decrease in sales of self-distributed products due to impact of spin-off of infusion and dialysis business units as AY PHARMACEUTICALS Co., Ltd. in July 2013 (approx. ¥4.9 billion), the impact of NHI drug price revisions, etc.

JINOMOTO. 3. (6) Other Business

					•		_
Other Business		AprJune 2014	Full-year Forecast	Progress	AprJune 2013	Change	
Net sales		19.7	91.1	22%	20.4	-0.7	*1
	Edible oils & Coffee products	0.5	-	-	0.5	-0.1	
Operating income		-0.4	-0.2	198%	0.0	-0.4	*2
	Edible oils & Coffee products	0.4	-	-	0.5	-0.1	
	Shared companywide expenses	-0.8	-3.6	23%	-0.7	-0.1	

^{*1} Decrease in sales due to a decrease in sales of logistics business etc.

^{*2} Decrease in income due to lower income in logistics business, despite higher income in wellness business.



3. (7) Net Sales by Business & Geographical Area

Upper row: Apr.-June 2014; lower row: Apr.-June 2013

Figures in parentheses represent YoY change.

	Japan		Asia		Americas		Euro	pe	Total		
Domestic Food	65.3	(-0.5)	1.4	(0.0)	3.4	(0.7)	0.9	(0.5)	71.0	(8.0)	
Products	65.7		1.4		2.7		0.4		70.1		
Overseas Food	2.3	(0.0)	50.0	(1.2)	14.8	(1.7)	7.3	(0.1)	74.4	(3.0)	
Products	2.2		48.8		13.1		7.2		71.4		
Bioscience Products	15.4	(0.4)	4.2	(-0.7)	17.0	(-0.4)	16.6	(-1.1)	53.2	(-1.9)	
& Fine Chemicals	15.0		4.9		17.4		17.7		55.0		
Pharmaceuticals	9.4	(-7.3)							9.4	(-7.3)	
- Haimace uncais	16.8								16.8		
Other Business	17.5	(-0.4)	2.2	(-0.3)	0.0	(0.0)			19.7	(-0.7)	
	17.9		2.4		0.0				20.4		
Total	109.8	(-7.8)	57.7	(0.3)	35.2	(2.0)	24.8	(-0.5)	227.6	(-6.1)	
i Olai	117.7		57.5		33.3		25.3		233.7		





3. (8) Operating Income by Business & Geographical Area

Upper row: Apr.-June 2014; lower row: Apr.-June 2013 Figures in parentheses represent YoY change.

	Japan		Asia		Americas		Europe		Other *		Total	
Domestic Food	6.0	(-1.0)	0.5	(-0.0)	0.3	(0.0)	0.1	(0.0)	-1.9	(-0.2)	5.0	(-1.2)
Products	7.0		0.5		0.3		0.1		-1.8		6.1	
Overseas Food	-0.4	(0.1)	8.8	(1.3)	2.0	(0.4)	-0.1	(-0.1)	-2.6	(-0.0)	7.8	(1.6)
Products	-0.5		7.6		1.6		0.0		-2.6		6.1	
Bioscience Products & Fine	2.2	(-1.1)	-0.3	(-0.7)	-0.7	(-0.6)	0.6	(-0.7)	-1.0	(1.4)	8.0	(-1.7)
Chemicals	3.3		0.4		-0.0		1.2		-2.4		2.5	
Pharmaceuticals	0.5	(-0.4)							-0.4	(0.1)	0.2	(-0.2)
	0.9								-0.5		0.4	
Other Business	0.1	(-0.4)	0.3	(-0.1)	-0.0	(-0.0)	0.1	(0.1)	-0.9	(-0.0)	-0.4	(-0.4)
	0.5		0.4		0.0		-0.0		-0.9		0.0	
Shared companywide	-3.1	(8.0)	-1.9	(0.3)	-1.0	(0.1)	-0.7	(0.1)	6.8	(-1.3)	0.0	
expenses, etc.	-3.9		-2.2		-1.1		-0.8		8.0		0.0	
Total	5.3	(-2.0)	7.4	(0.7)	0.6	(-0.2)	-0.0	(-0.5)			13.3	(-1.9)
Total	7.4	` ,	6.7	. ,	8.0	` ,	0.5	. ,			15.3	, ,

^{*} Other includes shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.





3. (9) Comments on Operating Income by Business & Geographical Area

Apr.-June FY2014 Change Compared with Same Period of Previous Year

1. Overseas Food Products

(¥ Billion)

[YoY change]

Japan +0.1; Asia +1.3; Americas +0.4; Europe -0.1; Other* -0.0; Total +1.6

Asia: Increase due to higher sales of consumer foods products, etc., despite negative effect of currency translation

2. Bioscience Products & Fine Chemicals

[YoY change] (¥ Billion)


Japan -1.1; Asia -0.7; Americas -0.6; Europe -0.7; Other* 1.4; Total -1.7

- (1) Japan: Decrease due to sweeteners, etc.
- (2) Americas: Decrease mainly due to feed-use amino acids, etc.



^{*} Shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.

(Reference) FY2014/Q1 Trends in Overseas Consumer Food Products



FY2014/Q1 Overseas Consumer Food Products Sales in Main Countries

> Thailand: approx. THB 7.9 billion

(+6% YoY, +1% on yen basis)

> Brazil: approx. BRL 0.17 billion

(+18% YoY, +13% on yen basis)

> Vietnam: approx. VND 1,359.0 billion

(+9% YoY, +12% on yen basis)


> Indonesia: approx. IDR 836.1 billion

(+45% YoY, +25% on yen basis)

> Philippines: approx. PHP 1.4 billion


(+12% YoY, +9% on yen basis)

JINOMOTO_® (Reference) Feed-Use Lysine Market Price and CBOT Spread* Trend



✓JINOMOTO (Reference) Change in Consolidated

Change in Consolidated First Quarter Net Sales



<Factors Influencing Net Sales in Recent Years >

- 1. Disposal of Calpis shares in October 2012
- Change to net figure method (the method of netting off sales and cost of goods sold and recording the net figure in the accounts) for business tie-ups in April 2013
- Spin-off of infusion and dialysis business units as AY PHARMACEUTICALS Co., Ltd. in July 2013
- Change in the method of recording sales promotion discounts, etc., in April 2014 (amounts of impact included are for reference only)



- ➤ Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- ➤ Unaudited figures are included in these materials for reference.
- ➤ Amounts presented in these materials are rounded off.